Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa … E Ngaimisi, A Habtewold, O Minzi, E Makonnen, S Mugusi, W Amogne, ... PloS one 8 (7), e67946, 2013 | 146 | 2013 |
Long‐term efavirenz autoinduction and its effect on plasma exposure in HIV patients E Ngaimisi, S Mugusi, OM Minzi, P Sasi, KD Riedel, A Suda, N Ueda, ... Clinical Pharmacology & Therapeutics 88 (5), 676-684, 2010 | 131 | 2010 |
Effect of Rifampicin and CYP2B6 Genotype on Long‐Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis E Ngaimisi, S Mugusi, O Minzi, P Sasi, KD Riedel, A Suda, N Ueda, ... Clinical Pharmacology & Therapeutics 90 (3), 406-413, 2011 | 90 | 2011 |
Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania S Mugusi, E Ngaimisi, M Janabi, O Minzi, M Bakari, KD Riedel, ... PloS one 7 (7), e40180, 2012 | 80 | 2012 |
Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania S Mugusi, E Ngaimisi, M Janabi, O Minzi, M Bakari, KD Riedel, ... PloS one 7 (7), e40180, 2012 | 80 | 2012 |
β-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans RJ Hardwick, W Amogne, S Mugusi, G Yimer, E Ngaimisi, A Habtewold, ... The Journal of infectious diseases 206 (7), 1012-1019, 2012 | 52 | 2012 |
CYP2B6* 6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria … BA Maganda, OMS Minzi, E Ngaimisi, AAR Kamuhabwa, E Aklillu The pharmacogenomics journal 16 (1), 88-95, 2016 | 49 | 2016 |
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment BA Maganda, E Ngaimisi, AAR Kamuhabwa, E Aklillu, OMS Minzi Malaria journal 14, 1-11, 2015 | 43 | 2015 |
Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method E Aklillu, S Mugusi, E Ngaimisi, MM Hoffmann, S König, V Ziesenitz, ... European journal of clinical pharmacology 67, 1139-1145, 2011 | 43 | 2011 |
CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans E Aklillu, L Odenthal-Hesse, J Bowdrey, A Habtewold, E Ngaimisi, ... BMC infectious diseases 13, 1-10, 2013 | 36 | 2013 |
Copy number variation of Fc gamma receptor genes in HIV-infected and HIV-tuberculosis co-infected individuals in sub-Saharan Africa LR Machado, J Bowdrey, E Ngaimisi, A Habtewold, O Minzi, E Makonnen, ... PloS one 8 (11), e78165, 2013 | 27 | 2013 |
SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine E Aklillu, A Habtewold, E Ngaimisi, G Yimer, S Mugusi, W Amogne, ... OMICS: A Journal of Integrative Biology 20 (9), 538-545, 2016 | 26 | 2016 |
Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: a combined analysis of phase II and phase III trials AK Jones, E Ngaimisi, M Gopalakrishnan, MA Young, CM Laffont Clinical Pharmacokinetics 60, 527-540, 2021 | 25 | 2021 |
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment E Ngaimisi, O Minzi, S Mugusi, P Sasi, KD Riedel, A Suda, N Ueda, ... Journal of Antimicrobial Chemotherapy 69 (12), 3311-3319, 2014 | 25 | 2014 |
Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania SF Mugusi, E Ngaimisi, MY Janabi, FM Mugusi, OMS Minzi, PG Sasi, ... Antiviral therapy 17 (2), 265-274, 2012 | 24 | 2012 |
Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa G Pillai, G Davies, P Denti, JL Steimer, H McIlleron, S Zvada, E Chigutsa, ... CPT: pharmacometrics & systems pharmacology 2 (8), 1-4, 2013 | 23 | 2013 |
Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator’s product OMS Minzi, IA Marealle, S Shekalaghe, O Juma, E Ngaimisi, M Chemba, ... Malaria journal 12, 1-8, 2013 | 22 | 2013 |
FDA approval summary: decitabine and cedazuridine tablets for myelodysplastic syndromes N Kim, KJ Norsworthy, S Subramaniam, H Chen, ML Manning, E Kitabi, ... Clinical Cancer Research 28 (16), 3411-3416, 2022 | 18 | 2022 |
Inter-laboratory development and cross validation of a chromatographic method for determination of lumefantrine in human plasma-A proficient capacity assessment of … OM Minzi, E Ngaimisi, DH Shewiyo, P Sasi, AM Ignace J Anal Bioanal Tech 3, 131, 2012 | 16 | 2012 |
Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy: a parallel prospective cohort … S Mugusi, A Habtewold, E Ngaimisi, W Amogne, G Yimer, O Minzi, ... Frontiers in Pharmacology 11, 506486, 2020 | 14 | 2020 |